This company has been marked as potentially delisted and may not be actively trading. LogicBio Therapeutics (LOGC) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsEarningsInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrendsBuy This Stock LOGC vs. FIGS, MYTE, ETD, HLF, SPTN, BLMN, KRUS, PLAY, CURV, and VLGEAShould you be buying LogicBio Therapeutics stock or one of its competitors? The main competitors of LogicBio Therapeutics include FIGS (FIGS), MYT Netherlands Parent B.V. (MYTE), Ethan Allen Interiors (ETD), Herbalife (HLF), SpartanNash (SPTN), Bloomin' Brands (BLMN), Kura Sushi USA (KRUS), Dave & Buster's Entertainment (PLAY), Torrid (CURV), and Village Super Market (VLGEA). These companies are all part of the "retail/wholesale" sector. LogicBio Therapeutics vs. FIGS MYT Netherlands Parent B.V. Ethan Allen Interiors Herbalife SpartanNash Bloomin' Brands Kura Sushi USA Dave & Buster's Entertainment Torrid Village Super Market LogicBio Therapeutics (NASDAQ:LOGC) and FIGS (NYSE:FIGS) are both small-cap retail/wholesale companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, institutional ownership, community ranking, valuation, risk, analyst recommendations, media sentiment, earnings and profitability. Does the media favor LOGC or FIGS? In the previous week, FIGS had 3 more articles in the media than LogicBio Therapeutics. MarketBeat recorded 3 mentions for FIGS and 0 mentions for LogicBio Therapeutics. LogicBio Therapeutics' average media sentiment score of 0.00 beat FIGS's score of -0.50 indicating that LogicBio Therapeutics is being referred to more favorably in the media. Company Overall Sentiment LogicBio Therapeutics Neutral FIGS Negative Do insiders and institutionals hold more shares of LOGC or FIGS? 46.1% of LogicBio Therapeutics shares are owned by institutional investors. Comparatively, 92.2% of FIGS shares are owned by institutional investors. 8.1% of LogicBio Therapeutics shares are owned by insiders. Comparatively, 22.3% of FIGS shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is LOGC or FIGS more profitable? FIGS has a net margin of 1.97% compared to LogicBio Therapeutics' net margin of -141.03%. FIGS's return on equity of 2.76% beat LogicBio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets LogicBio Therapeutics-141.03% -81.98% -52.13% FIGS 1.97%2.76%2.11% Which has more volatility & risk, LOGC or FIGS? LogicBio Therapeutics has a beta of 2.06, meaning that its share price is 106% more volatile than the S&P 500. Comparatively, FIGS has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Do analysts prefer LOGC or FIGS? FIGS has a consensus target price of $5.30, suggesting a potential upside of 34.01%. Given FIGS's stronger consensus rating and higher probable upside, analysts clearly believe FIGS is more favorable than LogicBio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LogicBio Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00FIGS 1 Sell rating(s) 3 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Does the MarketBeat Community believe in LOGC or FIGS? LogicBio Therapeutics received 44 more outperform votes than FIGS when rated by MarketBeat users. Likewise, 64.08% of users gave LogicBio Therapeutics an outperform vote while only 47.47% of users gave FIGS an outperform vote. CompanyUnderperformOutperformLogicBio TherapeuticsOutperform Votes9164.08% Underperform Votes5135.92% FIGSOutperform Votes4747.47% Underperform Votes5252.53% Which has preferable earnings and valuation, LOGC or FIGS? FIGS has higher revenue and earnings than LogicBio Therapeutics. LogicBio Therapeutics is trading at a lower price-to-earnings ratio than FIGS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLogicBio Therapeutics$287M0.62-$317M-$5.79-1.16FIGS$555.56M1.16$22.64M$0.02197.75 SummaryFIGS beats LogicBio Therapeutics on 14 of the 18 factors compared between the two stocks. Get LogicBio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LOGC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LOGC vs. The Competition Export to ExcelMetricLogicBio TherapeuticsCatalog & mail IndustryRetail SectorNASDAQ ExchangeMarket Cap$177.13M$157.53M$22.65B$7.35BDividend YieldN/AN/A170.23%4.34%P/E Ratio-1.16N/A21.4717.82Price / Sales0.620.294.1097.73Price / CashN/A3.2319.4134.64Price / Book0.751.065.593.98Net Income-$317M-$98.89M$781.29M$247.81M LogicBio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LOGCLogicBio Therapeutics0.5834 of 5 stars$6.74+0.1%N/AN/A$177.13M$287M-1.1662FIGSFIGS2.6098 of 5 stars$4.27+0.2%$5.56+30.3%-17.4%$692.34M$555.56M71.17310Analyst ForecastNews CoverageMYTEMYT Netherlands Parent B.V.2.0626 of 5 stars$7.93+0.6%$14.00+76.5%+100.3%$676.16M$881.44M-18.441,240ETDEthan Allen Interiors3.6882 of 5 stars$26.36-1.8%$32.00+21.4%-16.8%$670.34M$626.65M11.084,240Upcoming EarningsInsider TradeShort Interest ↓News CoverageHLFHerbalife4.2725 of 5 stars$6.61-1.2%$12.00+81.5%-27.4%$669.86M$4.99B2.6510,100Analyst DowngradeNews CoverageSPTNSpartanNash3.5251 of 5 stars$19.76+1.5%$15.00-24.1%+0.6%$668.80M$9.55B-1,976.0016,500Positive NewsBLMNBloomin' Brands3.8399 of 5 stars$7.64+8.4%$14.50+89.8%-70.6%$648.87M$3.95B-69.4587,000KRUSKura Sushi USA3.5333 of 5 stars$51.92+5.4%$77.20+48.7%-45.8%$626.47M$258.44M-76.352,100High Trading VolumePLAYDave & Buster's Entertainment4.2615 of 5 stars$17.68+3.4%$33.00+86.7%-62.8%$610.23M$2.13B8.7523,258Positive NewsCURVTorrid1.913 of 5 stars$5.24-0.2%$5.00-4.6%+14.5%$549.82M$1.10B34.932,060Positive NewsGap UpVLGEAVillage Super Market2.813 of 5 stars$35.63-0.4%N/A+26.2%$525.44M$2.28B10.277,180News CoveragePositive News Related Companies and Tools Related Companies FIGS Alternatives MYT Netherlands Parent B.V. Alternatives Ethan Allen Interiors Alternatives Herbalife Alternatives SpartanNash Alternatives Bloomin' Brands Alternatives Kura Sushi USA Alternatives Dave & Buster's Entertainment Alternatives Torrid Alternatives Village Super Market Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LOGC) was last updated on 4/21/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy LOGC Stock Free LOGC Stock Alerts